Global interest in microparticle platform technology continues to rise
[by Ji, Yong Jun] G2GBIO announced that it participated in two major global industry events: CPHI Worldwide 2025, the world’s largest pharmaceutical and biotechnology exhibition, held in Frankfurt, Germany, from October 28 to 30, and BIO-Europe 2025, which took place in Vienna, Austria, from November 3 to 5 (local time).
During the events, G2GBIO conducted 44 partnering meetings at CHPI Worldwide and 26 at BIO-Europe, engaging with global pharmaceutical and biotechnology companies. Leveraging its proprietary ‘microsphere platform’ technology, which enables high-dose and high-volume production, as well as the increased recognition gained following its KOSDAQ listing, the company held discussions on collaborative opportunities with firms developing novel peptide and small-molecule therapeutics.
The company reported that during CPHI Worldwide and BIO-Europe, it observed growing interest from pharmaceutical firms in the Middle East and North Africa (MENA), Europe, and Asia, particularly in its ‘high drug loading’ technology. Beyond engaging with raw material, excipient, and polymer manufacturers, G2GBIO also held discussions with Good Manufacturing Practice (GMP)-compliant ‘Fill Finish’ companies to explore potential collaboration throughout the entire microsphere production process. As a result, G2GBIO has agreed to continue follow-up meetings with partners previously engaged in discussions regarding product launches in major developed markets like the United States and Europe, with a focus on advancing GMP Fill Finish collaboration opportunities.
Furthermore, G2GBIO revealed that global pharmaceutical companies have expressed strong interest in its dementia treatment candidate, ‘GB-5001A’ (development code). The company added that GB-5001A, which is preparing to enter a multi-dose Phase 1b clinical trial, has attracted licensing inquiries from pharmaceutical companies in various regions, including the U.S., Europe, China, ASEAN countries, Canada, MENA, and Eastern Europe.
"Building on the progress we have made in obesity and diabetes treatments, we will focus our efforts on achieving notable advancements in dementia and schizophrenia therapies in the coming year," a G2GBIO official said.